Outlook Therapeutics (NASDAQ: OTLK) plunged nearly 24% in pre-market trading Thursday after the biotechnology company announced a discounted stock offering to raise capital for the U.S. commercial launch of Lytenava. While the financing strengthens the company’s resources ahead of commercialization, the substantial discount and accompanying warrants created immediate dilution concerns, overshadowing the recent FDA approval that had significantly improved the company’s outlook.

Discounted Offering Triggers Investor Selling

Outlook Therapeutics plans to sell approximately 55.6 million common shares, with each share accompanied by a warrant to purchase another share, for a combined price of $0.99. The offering represents roughly a 10% discount to Wednesday’s closing price. The warrants carry an exercise price of $1.10 and expire after five years, while underwriters have a 30-day option to purchase an additional 8.3 million shares and warrants.

The company expects to generate approximately $55 million in gross proceeds. Although the capital is intended to support the launch of Lytenava and general corporate needs, investors immediately focused on the dilution associated with the transaction. The timing is particularly significant because the financing arrives just as the company prepares to transition from development toward commercialization.

Lytenava Approval Creates a New Growth Opportunity

The financing comes after a major regulatory breakthrough for Outlook Therapeutics. Last month, the FDA approved Lytenava for wet age-related macular degeneration, giving the company a U.S.-approved product after a lengthy regulatory process.

The approval represented a significant reversal from December 2025, when the FDA rejected the company’s application and requested additional evidence. Following an appeal, the agency’s Office of New Drugs determined in May that additional clinical trials were not required.

Outlook describes Lytenava as the only FDA-approved bevacizumab formulation specifically developed for ophthalmic use. The treatment is already approved in the European Union and the United Kingdom, while the company expects to launch it in the U.S. before the end of 2026.

That commercial opportunity is now competing directly with near-term financing concerns. Investors must determine whether the capital raised today can accelerate commercialization enough to offset the dilution created by the offering.

Q3 Results Could Add Another Catalyst

Outlook Therapeutics is scheduled to report third-quarter results Friday, adding another potential source of volatility immediately after the financing announcement. Wall Street expects a loss of $0.07 per share, substantially narrower than the $0.44 per-share loss reported in the comparable period last year.

Analyst sentiment remains relatively positive despite the sharp pre-market decline. The stock carries a reported 12-month price target of $5.40, with three of four analysts maintaining Buy ratings and one rating the shares Hold. However, those expectations will increasingly depend on whether the company can translate regulatory approval into commercial execution.

Market Outlook

The immediate pressure on OTLK reflects a familiar biotech dilemma: raising capital can strengthen the balance sheet while simultaneously diluting existing shareholders. The company’s more than 60% gain in 2026 had already reflected heightened expectations surrounding Lytenava, making the discounted financing particularly sensitive for investors. Going forward, the Friday earnings report and further details on the U.S. launch will be critical in determining whether commercial prospects can restore investor confidence. The key risks remain additional financing needs, dilution and the pace at which Lytenava generates meaningful revenue.